For research use only. Not for therapeutic Use.
JNJ-1013（Cat No.:I041174）is a promising investigational compound developed by Johnson & Johnson, targeting specific molecular pathways in cancer cells. As a small molecule inhibitor, JNJ-1013 works by selectively interfering with the activity of proteins that drive tumor cell proliferation, survival, and metastasis. It is being studied for its potential to treat various solid tumors and hematologic malignancies, particularly in cases where traditional therapies have limited efficacy. Ongoing clinical trials are focused on evaluating its safety, tolerability, and effectiveness, with the aim of providing a new therapeutic option for cancer patients.
| CAS Number | 2597343-08-1 |
| Synonyms | N-[4-[4-[2-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-2-oxoethoxy]piperidin-1-yl]-2-methoxyphenyl]-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide |
| Molecular Formula | C46H55N9O7S |
| Purity | ≥95% |
| IUPAC Name | N-[4-[4-[2-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-2-oxoethoxy]piperidin-1-yl]-2-methoxyphenyl]-6-(1H-pyrazol-5-yl)pyridine-2-carboxamide |
| InChI | InChI=1S/C46H55N9O7S/c1-27(29-10-12-30(13-11-29)41-28(2)47-26-63-41)49-44(59)38-23-32(56)24-55(38)45(60)42(46(3,4)5)52-40(57)25-62-33-17-20-54(21-18-33)31-14-15-36(39(22-31)61-6)51-43(58)37-9-7-8-34(50-37)35-16-19-48-53-35/h7-16,19,22,26-27,32-33,38,42,56H,17-18,20-21,23-25H2,1-6H3,(H,48,53)(H,49,59)(H,51,58)(H,52,57)/t27-,32+,38-,42+/m0/s1 |
| InChIKey | MHRNVFQJUUXQIG-VIFUUBRESA-N |
| SMILES | CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COC4CCN(CC4)C5=CC(=C(C=C5)NC(=O)C6=CC=CC(=N6)C7=CC=NN7)OC)O |
